Volume 21 Issue 8
Aug.  2023
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2023  >  21(8): 1295-1298
WANG Rui, CHEN Yufuo, ZHANG Tiantian, LIU Yang, ZHANG Shanshan, LI Yumei. Effect of camrelizumab in combination with apatinib on health-related quality of life in patients with advanced liver cancer[J]. Chinese Journal of General Practice, 2023, 21(8): 1295-1298. doi: 10.16766/j.cnki.issn.1674-4152.003106
Citation: WANG Rui, CHEN Yufuo, ZHANG Tiantian, LIU Yang, ZHANG Shanshan, LI Yumei. Effect of camrelizumab in combination with apatinib on health-related quality of life in patients with advanced liver cancer[J]. Chinese Journal of General Practice, 2023, 21(8): 1295-1298. doi: 10.16766/j.cnki.issn.1674-4152.003106
shu

Effect of camrelizumab in combination with apatinib on health-related quality of life in patients with advanced liver cancer

doi: 10.16766/j.cnki.issn.1674-4152.003106

  • Department of Medical Oncology, the First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, China

Funds:

 2208085MH246

 2019byyfyjq03

 by51201215

  • Received Date: 2023-03-05
    Available Online: 2023-09-13
    Abstract
  •   Objective  To evaluate the efficacy of combination therapy with camrelizumab and apatinib as a first-line treatment for advanced hepatocellular carcinoma (HCC) and its impact on patients ' quality of life.  Methods  The advanced HCC patients who received the first-line treatment of apatinib combined with (31 cases) or without (23 cases) camrelizumab were selected in the First Affiliated Hospital of Bengbu Medical College from January 2020 to June 2022, the clinical data and patient-reported outcome (PRO) scales (EORTC QLQ-C30 and HCC18) were collected. Objective efficacy and the effect on HRQoL were evaluated.  Results  The combination group was higher in the objective response rate (22.58% vs. 8.69%, χ2=0.969, P=0.325) and disease control rate (70.97% vs. 56.52%, χ2=1.208, P=0.271) compared with the single drug group, however, the difference was not statistically significant. The mPFS in the combination group was prolonged compared to the single drug group (5.60 months vs. 3.50 months, P=0.002). Both groups had similar C30 and HCC18 scores at baseline. After 4 cycles of treatment, C30 emotional (t=2.093, P=0.041) and cognitive function (U=193.000, P=0.003) scores in combination group were higher than those in single drug group. Nausea and vomiting (U=252.500, P=0.039) and loss of appetite (U=244.000, P=0.031) were less severe than single drug group. Body change (U=250.000, P=0.044) and fever (U=237.500, P=0.026) in HCC18 were less severe than those in single drug group.  Conclusion  Camrelizumab in combination with apatinib for the first-line treatment of advanced HCC patients can improve the efficacy and health-related quality of life of patients.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    李照, 朱继业. 《原发性肝癌诊疗指南(2022年版)》解读[J]. 临床肝胆病杂志, 2022, 38(5): 1027-1029. doi: 10.3969/j.issn.1001-5256.2022.05.010

    LI Z, ZHU J Y. Interpretation of Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. Journal of Clinical Hepatology, 2022, 38(5): 1027-1029 doi: 10.3969/j.issn.1001-5256.2022.05.010
    [2]
    NORMAN E M L, WEIL J, PHILIP J. Hepatocellular carcinoma and its impact on quality of life: a review of the qualitative literature[J]. Eur J Cancer Care (Engl), 2022, 31(6): e13672. DOI: 10.1111/ecc.13672.
    [3]
    李萍, 刘文红, 赵萌, 等. 原发性肝癌肝动脉化疗栓塞术术前营养风险筛查的意义及个体化营养干预效果分析[J]. 中华全科医学, 2021, 19(7): 1087-1090. doi: 10.16766/j.cnki.issn.1674-4152.001991

    LI P, LIU W H, ZHAO M, et al. Significance of nutritional risk screening before transcatheter arterial chemoembolization for primary liver cancer and the effect of individualised nutritional intervention[J]. Chinese Journal of General Practice, 2021, 19(7): 1087-1090. doi: 10.16766/j.cnki.issn.1674-4152.001991
    [4]
    SILVEIRA A, SEQUEIRA T, GONCALVES J, et al. Patient reported outcomes in oncology: changing perspectives-a systematic review[J]. Health Qual Life Outcomes, 2022, 20(1): 82. doi: 10.1186/s12955-022-01987-x
    [5]
    YOUNOSSI Z, AGGARWAL P, SHRESTHA I, et al. The burden of non-alcoholic steatohepatitis: a systematic review of health-related quality of life and patient-reported outcomes[J]. JHEP Rep, 2022, 4(9): 100525. DOI: 10.1016/j.jhepr.2022.100525.
    [6]
    RIMASSA L, DANESI R, PRESSIANI T, et al. Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma[J]. Cancer Treat Rev, 2019, 77: 20-28. doi: 10.1016/j.ctrv.2019.05.004
    [7]
    ZOU H M, LI M, LEI Q, et al. Economic burden and quality of life of hepatocellular carcinoma in greater China: a systematic review[J]. Front Public Health, 2022, 10: 801981. DOI: 10.3389/fpubh.2022.801981.
    [8]
    CARROZZONO D, PATIERNO C, GUIDI J, et al. Clinimetric criteria for patient-reported outcome measures[J]. Psychother Psychosom, 2021, 90(4): 222-232. doi: 10.1159/000516599
    [9]
    FREEMANTLE N, MOLLON P, MEYER T, et al. Quality of life assessment of cabozantinib in patients with advanced hepatocellular carcinoma in the CELESTIAL trial[J]. Eur J Cancer, 2022, 168: 91-98. DOI: 10.1016/j.ejca.2022.03.021.
    [10]
    XIA S J, PAN Y, LIANG Y L, et al. The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma[J]. EBioMedicine, 2020, 51: 102610. DOI: 10.1016/j.ebiom.2019.102610.
    [11]
    CHEN S, CAO Q, WEN W, et al. Targeted therapy for hepatocellular carcinoma: challenges and opportunities[J]. Cancer Lett, 2019, 460: 1-9. DOI: 10.1016/j.canlet.2019.114428.
    [12]
    SANGRO B, SAROBE P, HERVAS-STUBBS S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8): 525-543. doi: 10.1038/s41575-021-00438-0
    [13]
    REN Z G, XU J M, BAI Y X, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. doi: 10.1016/S1470-2045(21)00252-7
    [14]
    LIU Z Y, LIU X, LIANG J X, et al. Immunotherapy for hepatocellular carcinoma: current status and future prospects[J]. Front Immunol, 2021, 12: 765101. DOI: 10.3389/fimmu.2021.765101.
    [15]
    GALLE P R, FINN R S, QIN S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(7): 991-1001. doi: 10.1016/S1470-2045(21)00151-0
    [16]
    KELLEY R K, SANGRO B, HARRIS W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase Ⅰ/Ⅱ study[J]. J Clin Oncol, 2021, 39(27): 2991-3001. doi: 10.1200/JCO.20.03555
    [17]
    FIRKINS J L, TARTER R, DRIESSBACK M, et al. A closer look at quality of life in the hepatocellular carcinoma literature[J]. Qual Life Res, 2021, 30(6): 1525-1535. doi: 10.1007/s11136-021-02789-2
    [18]
    PALA L, SALA I, ORIECUIA C, et al. Association of anticancer immune checkpoint inhibitors with patient-reported outcomes assessed in randomized clinical trials: a systematic review and meta-analysis[J]. JAMA Netw Open, 2022, 5(8): e2226252. DOI: 10.1001/jamanetworkopen.2022.26252.
    [19]
    周慧, 林颖, 周国进, 等. 《将患者报告结局纳入临床研究的伦理考量: PRO伦理指南》解读[J]. 中国全科医学, 2023, 26(4): 395-400. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202304016.htm

    ZHOU H, LIN Y, ZHOU G J, et al. Interpretation of Ethical Considerations for the Inclusion of Patient-Reported Outcomes in Clinical Research(the PRO Ethics Guidelines)[J]. Chinese General Practice, 2023, 26(4): 395-400. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX202304016.htm
    [20]
    LEITH A, KⅡSKINEN U, GIRVAN A C, et al. Physician and patient reported symptom concordance and association with quality of life in hepatocellular carcinoma[J]. Future Oncol, 2022, 18(33): 3727-3740. doi: 10.2217/fon-2022-0202
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(5)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (323) PDF downloads(11) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return